OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like g...OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.展开更多
目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD...目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD同源物3(Smad homolog 3,SMAD3)通路在调控病理性心肌纤维化的作用。方法:建立小鼠心脏纤维化模型,分别于模型组和假手术组中检测E4BP4的表达差异。分离和培养原代心脏成纤维细胞,血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)刺激增殖活化,分别转染E4BP4过表达质粒(Ang Ⅱ+E4BP4组)、E4BP4干扰质粒(Ang Ⅱ+siE4BP4组)、Ang Ⅱ组和未经Ang Ⅱ处理的对照组。免疫荧光检测α-肌动蛋白(α-smooth muscle actin,α-SMA)荧光强度,细胞增殖检测试剂盒测定细胞活力,聚合酶链式反应检测E4BP4、α-SMA、Ⅰ型胶原蛋白(collagen type Ⅰ,Collagen Ⅰ)和Ⅲ型胶原蛋白(collagen type Ⅲ,Collagen Ⅲ)的表达,蛋白质印迹检测TGF-β1、AMPK和SMAD3的蛋白表达。结果:与假手术组比较,模型组心肌纤维化程度(38.46±1.21 vs. 3.39±0.39,t=-78.564,P=0.000)、E4BP4蛋白表达量(0.96±0.03 vs. 0.75±0.03,t=-11.480,P=0.000)均明显增加。体外实验发现,与Ang Ⅱ+E4BP4组比较,Ang Ⅱ+siE4BP4组在平均荧光强度(0.05±0.01 vs. 0.42±0.03,F=677.591,P=0.000)、细胞活力(91.30±2.39vs.123.74±2.60,F=132.696,P=0.000)、α-SMA(1.26±0.09vs.3.59±0.86,F=52.274,P=0.000)、Collagen Ⅰ(1.16±0.11vs.3.79±0.89,F=55.336,P=0.000)、Collagen Ⅲ(1.23±0.13 vs. 2.92±0.36,F=119.929,P=0.000)、TGF-β1(0.66±0.04 vs. 0.96±0.02,F=142.954,P=0.000)和p-SMAD3/SMAD3(0.81±0.03 vs. 1.37±0.02,F=739.609,P=0.000)的水平明显降低,而p-AMPK/AMPK的表达量在Ang Ⅱ+siE4BP4组明显高于Ang Ⅱ+E4BP4组(0.89±0.01 vs. 0.58±0.02,F=284.541,P=0.000)。结论:E4BP4是纤维化调控的关键因子,抑制其表达可通过激活AMPK进而抑制TGF-β1/SMAD3通路发挥抗纤维化作用。展开更多
Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinom...Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.展开更多
基金supported by National Natural Science Foundation of China(81502123 and81330081)Natural Science Foundation of Anhui Province(1308085QH130)Anhui Province Nature Science Foundation in University(KJ2014A119)
文摘OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.
文摘目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD同源物3(Smad homolog 3,SMAD3)通路在调控病理性心肌纤维化的作用。方法:建立小鼠心脏纤维化模型,分别于模型组和假手术组中检测E4BP4的表达差异。分离和培养原代心脏成纤维细胞,血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)刺激增殖活化,分别转染E4BP4过表达质粒(Ang Ⅱ+E4BP4组)、E4BP4干扰质粒(Ang Ⅱ+siE4BP4组)、Ang Ⅱ组和未经Ang Ⅱ处理的对照组。免疫荧光检测α-肌动蛋白(α-smooth muscle actin,α-SMA)荧光强度,细胞增殖检测试剂盒测定细胞活力,聚合酶链式反应检测E4BP4、α-SMA、Ⅰ型胶原蛋白(collagen type Ⅰ,Collagen Ⅰ)和Ⅲ型胶原蛋白(collagen type Ⅲ,Collagen Ⅲ)的表达,蛋白质印迹检测TGF-β1、AMPK和SMAD3的蛋白表达。结果:与假手术组比较,模型组心肌纤维化程度(38.46±1.21 vs. 3.39±0.39,t=-78.564,P=0.000)、E4BP4蛋白表达量(0.96±0.03 vs. 0.75±0.03,t=-11.480,P=0.000)均明显增加。体外实验发现,与Ang Ⅱ+E4BP4组比较,Ang Ⅱ+siE4BP4组在平均荧光强度(0.05±0.01 vs. 0.42±0.03,F=677.591,P=0.000)、细胞活力(91.30±2.39vs.123.74±2.60,F=132.696,P=0.000)、α-SMA(1.26±0.09vs.3.59±0.86,F=52.274,P=0.000)、Collagen Ⅰ(1.16±0.11vs.3.79±0.89,F=55.336,P=0.000)、Collagen Ⅲ(1.23±0.13 vs. 2.92±0.36,F=119.929,P=0.000)、TGF-β1(0.66±0.04 vs. 0.96±0.02,F=142.954,P=0.000)和p-SMAD3/SMAD3(0.81±0.03 vs. 1.37±0.02,F=739.609,P=0.000)的水平明显降低,而p-AMPK/AMPK的表达量在Ang Ⅱ+siE4BP4组明显高于Ang Ⅱ+E4BP4组(0.89±0.01 vs. 0.58±0.02,F=284.541,P=0.000)。结论:E4BP4是纤维化调控的关键因子,抑制其表达可通过激活AMPK进而抑制TGF-β1/SMAD3通路发挥抗纤维化作用。
文摘Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.
